Investors

Press Releases

Overview
Press Releases
Events + Presentations
Company Information
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
News Alerts

Recent Press Releases

Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

January 20, 2022

Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference

January 18, 2022

Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

January 4, 2022

Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR

December 23, 2021

Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 12, 2021

Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event

November 11, 2021

Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference

November 10, 2021

Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting

November 1, 2021

Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements

October 12, 2021

Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board

September 14, 2021

Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit

August 11, 2021

Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 10, 2021

Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR

July 13, 2021

Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 13, 2021

Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer

May 11, 2021

Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit

May 7, 2021

Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum

April 26, 2021

Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval

April 13, 2021

Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update

March 29, 2021

Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

March 3, 2021

Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors

February 23, 2021

Vallon Pharmaceuticals Announces Closing of Initial Public Offering

February 12, 2021

Vallon Pharmaceuticals Announces Pricing of Initial Public Offering

February 9, 2021

Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting

January 19, 2021

Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting

January 8, 2021

Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR

November 9, 2020

Vallon Newsroom

Sign Up for Updates

© 2022 Vallon Pharmaceuticals | Terms of Use | Privacy Policy

ADAIR is an investigational new drug product and has not yet been approved by the FDA. All trademarks shown are the property of their respective owners.